Compare Mesoblast Limited (MESO) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Petróleo Brasileiro SA — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Petróleo Brasileiro SA trades at $18.53 (market cap $108.78B). The key difference: Petróleo Brasileiro SA is far larger — about 50.1× Mesoblast Limited's market cap, and Petróleo Brasileiro SA pays a 9.81% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PBR | |
|---|---|---|
Market Cap | $2.17B | $108.78B |
Sector | Technology | Technology |
52-Week High | $20.96 | $22.03 |
52-Week Low | $12.88 | $11.54 |
Enterprise Value | $2.17B | $171.32B |
Dividend Yield | — | 9.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Petrobras (PBR) trades at $18.19, up 1.22% with bullish technical indicators and strong fundamentals. The stock shows robust profitability with 21.47% net margins and attractive valuation at 5.73 P/E. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed estimates. The company maintains strong cash flow generation of $197.5B operating cash flow in 2025 and recently announced strategic acquisitions and renewable energy investments.
PBR presents compelling value with deep discount valuation and 50% analyst buy ratings. Key opportunities include production growth initiatives and dividend sustainability, while risks involve commodity price volatility and geopolitical factors in Latin American operations. The stock's current technical strength combined with fundamental undervaluation supports a positive medium-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
